دورية أكاديمية

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

التفاصيل البيبلوغرافية
العنوان: Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
المؤلفون: Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Caglevic, C., Chung, H.C., Muro, K., Van Cutsem, E., Kobie, J., Cristescu, R., Aurora-Garg, D., Lu, J., Shih, C.-S., Adelberg, D., Cao, Z.A., Fuchs, C.S.
المصدر: In Annals of Oncology September 2021 32(9):1127-1136
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2021.05.803